Skip to Main Content

Paper Details

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Clin Cancer Res
12
2023
Author NameAffiliation
Bartosz ChmielowskiJonsson Comprehensive Cancer Center, University of California Los Angeles
Ezra E W CohenMoores Cancer Center at university of california san diego Health
  • 1 - 2

Datasets

Release 1.2